NCT06965309

Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)

Dose-escalation Study to Assess the Safety, Tolerability, and Preliminary Efficacy of HN2301 in Patients With Refractory Myasthenia Gravis (MG)

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is an investigator-initiated trial designed to evaluate the safety, and efficacy of HN2301 in refractory myasthenia gravis

Detailed description

This study is a prospective exploratory clinical trial in subjects with refractory myasthenia gravis. The objective is to evaluate the safety, initial efficacy of HN2301injection in refractory myasthenia gravis.

Conditions

• Refractory Myasthenia Gravis

Interventions

Type	Name	Description
DRUG	HN2301 injection	Description: Three dose groups were set up, starting from the low dose group and climbing to explore the safe and effective dose.

Timeline

• Start date: 2026-01-19
• Primary completion: 2026-02-11
• Completion: 2026-02-11
• First posted: 2025-05-11
• Last updated: 2026-02-12

Locations

1 site across 1 country: China